Cryptococcosis in sarcoidosis: cryptOsarc, a comparative study of 18 cases
…, J Pouget, J Serratrice, JP Brion, F Vaylet… - … Journal of Medicine, 2013 - academic.oup.com
Aim: To describe the main characteristics and the treatment of cryptococcosis in patients with
sarcoidosis. Design: Multicenter study including all patients notified at the French National …
sarcoidosis. Design: Multicenter study including all patients notified at the French National …
Pulmonary nocardiosis in immunocompetent patients: can COPD be the only risk factor?
F Riviere, M Billhot, C Soler, F Vaylet… - European Respiratory …, 2011 - Eur Respiratory Soc
3 Dennstedt FE, Greenberg SD, Kim HS, et al. Pulmonary lymphangitic carcinomatosis from
occult stomach carcinoma in young adults: an unusual cause of dyspnea. Chest 1983; 84: …
occult stomach carcinoma in young adults: an unusual cause of dyspnea. Chest 1983; 84: …
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 …
…, E Dansin, M Poudenx, O Molinier, F Vaylet… - The Lancet, 2011 - thelancet.com
Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
lung cancer (NSCLC) in fit, non-elderly adults, but monotherapy is recommended …
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine …
…, P Fournel, L Falchero, M Poudenx, F Vaylet… - Journal of Clinical …, 2012 - ascopubs.org
Purpose This phase III study investigated whether continuation maintenance with
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …
gemcitabine or switch maintenance with erlotinib improves clinical outcome compared with …
[HTML][HTML] Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the …
…, Y Martinet, JP Gury, N Baize, P Dumont, F Vaylet… - Annals of …, 2015 - Elsevier
IFCT study administering 7.5 mg/kg Bevacizumab plus chemotherapy after chemotherapy
induction did not improve outcomes in extensive SCLC patients. Background This randomized …
induction did not improve outcomes in extensive SCLC patients. Background This randomized …
[HTML][HTML] Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy–results from the randomised …
Background Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic
cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD…
cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD…
[HTML][HTML] Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell …
…, A Ducolone, JL Breton, D Braun, B Lebeau, F Vaylet… - Annals of oncology, 2005 - Elsevier
Background Taxotere® (docetaxel) at the dose of 75 mg/m 2 every 3 weeks is a standard
therapy for pretreated non-small-cell lung cancer (NSCLC). The aim of this study was to …
therapy for pretreated non-small-cell lung cancer (NSCLC). The aim of this study was to …
[HTML][HTML] Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative …
Background EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors
(TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-…
(TKI). To better understand these features, we reviewed all cases of EGFR-mutated non-…
[HTML][HTML] Immunohistochemistry to identify EGFR mutations or ALK rearrangements in patients with lung adenocarcinoma
…, A Bernheim, M Alifano, F Leroy-Ladurie, F Vaylet… - Annals of oncology, 2012 - Elsevier
Background Immunohistochemistry has been proposed as a specific and sensitive method
to identify EGFR mutations or ALK rearrangements in lung tumours. Patients and methods …
to identify EGFR mutations or ALK rearrangements in lung tumours. Patients and methods …
A Comparative and Integrative Approach Identifies ATPase Family, AAA Domain Containing 2 as a Likely Driver of Cell Proliferation in Lung Adenocarcinoma
…, S Camilleri-Bröet, F Vaylet, F Leroy-Ladurie… - Clinical cancer …, 2012 - AACR
… As the number of ever smokers was higher in the group of tumors expressing the proliferative
cluster f, we tested the association of smoking status with each CONEXIC module using …
cluster f, we tested the association of smoking status with each CONEXIC module using …